Revelation Biosciences (NASDAQ:REVB) Releases Earnings Results, Beats Expectations By $0.24 EPS

Revelation Biosciences (NASDAQ:REVB) issued its quarterly earnings results on Thursday. The company reported ($5.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.16) by $0.24, FiscalAI reports.

Revelation Biosciences Stock Up 9.3%

REVB traded up $0.33 on Friday, reaching $3.89. 14,458 shares of the company traded hands, compared to its average volume of 33,858. The company has a market cap of $2.66 million, a P/E ratio of -0.05 and a beta of -0.13. Revelation Biosciences has a one year low of $3.08 and a one year high of $40.60. The firm has a fifty day simple moving average of $5.51 and a two-hundred day simple moving average of $7.90.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, Revelation Biosciences currently has a consensus rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases.

Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.

Revelation Biosciences is headquartered in San Diego, California, and has focused primarily on advancing its pipeline through preclinical and clinical development rather than marketing approved commercial products.